New data from helios-b phase 3 study demonstrate lower rates of gastrointestinal events in attr-cm patients treated with vutrisiran

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced results from new analyses of the helios-b phase 3 study of amvuttra® (vutrisiran), an rnai therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (attr-cm) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hattr-pn) in adults. data from a post hoc analysis of the helios-b.
ALNY Ratings Summary
ALNY Quant Ranking